Business Context and Reporting Period
This Form 8-K is a current report filed by Inmune Bio, Inc. (INMB) on July 19, 2021. The company is a Nevada corporation focused on developing therapeutics targeting innate immunity. The report details an upcoming scientific presentation scheduled for late July 2021.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event notification and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported in this filing. The primary event is the announcement of a scientific presentation at the Alzheimer's Association International Congress 2021, to be held in a hybrid format in Denver and online from July 26-30, 2021.
Outlook and Management Commentary
- Scientific Presentation: The Company will present a poster at the Alzheimer's Association International Congress 2021.
- Key Personnel: Dr. Malu Tansey of the University of Florida College of Medicine, a co-inventor of XPro1595 (pegipanermin), will deliver a plenary talk titled "Therapeutic Approaches Targeting Innate Immunity in AD."
- Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Key Facts for Investor Verification
- Verify the content and data presented in the poster at the Alzheimer's Association International Congress 2021.
- Review the full text of the press release attached as Exhibit 99.1 for additional details on the plenary talk.
- Confirm the status of the XPro1595 (pegipanermin) development program following the presentation.